⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612165 | 1.00 | — | — | |
| SCHEMBL3139179 | 0.75 | — | — | |
| SCHEMBL4067490 | 0.72 | — | — | |
| SCHEMBL933420 | 0.69 | — | — | |
| SCHEMBL123787 | 0.69 | — | — | |
| SCHEMBL6439589 | 0.69 | — | — | |
| SCHEMBL9168563 | 0.69 | — | — | |
| SCHEMBL2385226 | 0.69 | — | — | |
| SCHEMBL6967678 | 0.67 | — | — | |
| SCHEMBL1032835 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111035653-B | Compositions and methods for treating multiple sclerosis | 武汉广行科学研究有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115400225-A | Ligand-bound gold clusters, compositions and methods for treating liver cirrhosis | 武汉广行科学研究有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115317510-A | Gold clusters, compositions and methods for treating depression | 深圳深见医药科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-113398279-B | Ligand-bound gold clusters, compositions and methods for treating liver cirrhosis | 武汉广行科学研究有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-111568922-B | Treatment of atypical antipsychotic-induced adverse reactions | 深圳深见医药科技有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-113398279-A | Ligand-bound gold clusters, compositions and methods for treating liver cirrhosis | 武汉广行科学研究有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-112675196-A | Compositions and methods for treating diabetes | 深圳深见医药科技有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-111568922-A | Treatment of atypical antipsychotic-induced adverse reactions | 深圳深见医药科技有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-111035653-A | Compositions and methods for treating multiple sclerosis | 武汉广行科学研究有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-0827408-A1 | METHOD OF ADMINISTRATION OF IGF-I | GENENTECH, INC. (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1996037216-A1 | METHOD OF ADMINISTRATION OF IGF-I | GENENTECH, INC. (US) | 1996-11-28 | — | — | WO | disclosed |